198 related articles for article (PubMed ID: 24725686)
1. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
[TBL] [Abstract][Full Text] [Related]
3. Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Farrell PJ
Nat Clin Pract Oncol; 2005 Jan; 2(1):14-5. PubMed ID: 16264847
[No Abstract] [Full Text] [Related]
4. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Hong RL; Ting LL; Ko JY; Hsu MM; Sheen TS; Lou PJ; Wang CC; Chung NN; Lui LT
J Clin Oncol; 2001 Dec; 19(23):4305-13. PubMed ID: 11731513
[TBL] [Abstract][Full Text] [Related]
5. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
[TBL] [Abstract][Full Text] [Related]
6. A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Chua DT; Sham JS; Au GK
Head Neck; 2004 Feb; 26(2):118-26. PubMed ID: 14762880
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
Wang WY; Twu CW; Chen HH; Jiang RS; Wu CT; Liang KL; Shih YT; Chen CC; Lin PJ; Liu YC; Lin JC
Cancer; 2013 Mar; 119(5):963-70. PubMed ID: 23065693
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
Chan AT; Ma BB; Lo YM; Leung SF; Kwan WH; Hui EP; Mok TS; Kam M; Chan LS; Chiu SK; Yu KH; Cheung KY; Lai K; Lai M; Mo F; Yeo W; King A; Johnson PJ; Teo PM; Zee B
J Clin Oncol; 2004 Aug; 22(15):3053-60. PubMed ID: 15284255
[TBL] [Abstract][Full Text] [Related]
9. Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.
Lin JC; Jan JS; Chen KY; Hsu CY; Liang WM; Wang WY
Head Neck; 2003 Jun; 25(6):438-50. PubMed ID: 12784235
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china.
Chen Y; Liu MZ; Liang SB; Zong JF; Mao YP; Tang LL; Guo Y; Lin AH; Zeng XF; Ma J
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1356-64. PubMed ID: 18472356
[TBL] [Abstract][Full Text] [Related]
12. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Kwong DL; Sham JS; Au GK; Chua DT; Kwong PW; Cheng AC; Wu PM; Law MW; Kwok CC; Yau CC; Wan KY; Chan RT; Choy DD
J Clin Oncol; 2004 Jul; 22(13):2643-53. PubMed ID: 15226332
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.
Chua DT; Ma J; Sham JS; Mai HQ; Choy DT; Hong MH; Lu TX; Min HQ
J Clin Oncol; 2005 Feb; 23(6):1118-24. PubMed ID: 15657403
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Golden DW; Rudra S; Witt ME; Nwizu T; Cohen EE; Blair E; Stenson KM; Vokes EE; Haraf DJ
Oral Oncol; 2013 Mar; 49(3):277-82. PubMed ID: 23102863
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Lin JC; Wang WY; Liang WM; Chou HY; Jan JS; Jiang RS; Wang JY; Twu CW; Liang KL; Chao J; Shen WC
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1342-8. PubMed ID: 17449194
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
19. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials.
Chua DT; Ma J; Sham JS; Mai HQ; Choy DT; Hong MH; Lu TX; Au GK; Min HQ
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1300-6. PubMed ID: 16750333
[TBL] [Abstract][Full Text] [Related]
20. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
